Description: ADMA Biologics, Inc., a late stage biopharmaceutical company, develops, manufactures, and intends to market plasma-based biologics for the treatment and prevention of infectious diseases. Its lead product candidate, RI-002, which is in Phase III clinical trial, is intended for the treatment of primary immune deficiency disease. RI-002 is an injectable immune globulin derived from human plasma enriched with high levels of naturally occurring polyclonal antibodies, as well as high levels of antibodies targeted to respiratory syncytial virus. The company also operates ADMA BioCenters, which are plasma collection centers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.
Home Page: www.admabiologics.com
ADMA Technical Analysis
465 State Route 17
Ramsey,
NJ
07446
United States
Phone:
201 478 5552
Officers
| Name | Title |
|---|---|
| Mr. Adam S. Grossman | Co-Founder, Pres, CEO & Director |
| Dr. Jerrold B. Grossman D.P.S., Ph.D. | Co-Founder & Vice Chairman |
| Mr. Brian Lenz CPA, CPA | Exec. VP, CFO & GM of ADMA BioCenters |
| Ms. Kaitlin Kestenberg | VP of Compliance, Project Management & Clinical Operations |
| Mr. Michael Goldstein | Sr. Director & Gen. Counsel |
| Mr. Michael Least | VP of Sales & Commercial Operations |
| Mr. Drew Pantello | VP of Marketing & Corp. Devel. |
| Mr. Neal C. Fitzpatrick | VP of Sales |
| Dr. Gene A. Wetzstein BCOP, Pharm.D. | Exec. Director & Head of Scientific Engagement |
| Ms. Cyndi Tolman | Sr. VP of Plasma Services |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 7.7007 |
| Price-to-Sales TTM: | 5.9412 |
| IPO Date: | 2013-10-17 |
| Fiscal Year End: | December |
| Full Time Employees: | 527 |